Co-Diagnostics, Inc.
NASDAQ: CODX0.00 n/a
+0.00%(+0.00)
Key facts
- Exchange
- NASDAQ
- Sector
- Healthcare
- Industry
- Biotechnology
- CEO
- Dwight Egan
- Employees
- 112
- Headquarters
- Salt Lake City, United States
- IPO year
- 2017
- Market cap
- $4.0M
- Website
- https://co-dx.com
Loading CODX…
Loading profile data…Frequently asked questions about CODX
What does Co-Diagnostics, Inc. (CODX) do?
Co-Diagnostics, Inc. operates as a molecular diagnostics company that develops, manufactures, and sells reagents used for diagnostic tests that function through the detection and/or analysis of nucleic acid molecules in the United States and internationally. The company offers Co-Dx PCR platform, a polymerase chain reaction testing to patients i...
Where does CODX trade?
Co-Diagnostics, Inc. (CODX) trades on the NASDAQ.
What sector is CODX in?
Co-Diagnostics, Inc. (CODX) operates in the Healthcare sector, specifically in the Biotechnology industry.
Who is the CEO of Co-Diagnostics, Inc.?
Dwight Egan is the chief executive officer of Co-Diagnostics, Inc. (CODX).
Where is Co-Diagnostics, Inc. headquartered?
Co-Diagnostics, Inc. is headquartered in United States.
Does CODX pay a dividend?
Co-Diagnostics, Inc. (CODX) does not currently pay a regular dividend. Check the dividends tab for any historical or special distributions.
When did CODX go public?
Co-Diagnostics, Inc. (CODX) completed its initial public offering in 2017.